Study at ASCO reveals an alternative protocol - effectively treats lung cancer patients

June 14, 2010 - PRLog -- 2010 ASCO annual meeting was held from 4th – 8th June, 2010 in Chicago, Illinois. The conference attracted around 35,000 delegates. American Society of Clinical Oncology (ASCO) is the world’s leading professional organization committed in improving cancer care through research and educational activities. 2010 ASCO Annual Meeting was the world’s largest forum for the cutting-edge scientific and educational developments in oncology with a focus on advancing quality through innovation.
      
The lead study author and ASCO member, Aradeep Chatterjee who is attached with the Critical Cancer Management Research Centre & Clinic (CCMRCC), Kolkata, India says “Lung cancer is one of the major silent killers usually diagnosed at the advance stage where surgical cure is not possible. Till now, only 16% patients undergoing conventional cancer treatments can survive up to 5 years. Our study involves non small cell lung cancer (NSCLC) which represents about 85% of all lung cancer types. We have conducted a phase-II single arm clinical trial involving 95 inoperable lung cancer patients trying an investigational cancer treatment ‘Psorinum Therapy’. The study documents significant complete and partial tumor regression rates and improvement of the survival span of the patients. The study also confirms that Psorinum Therapy do not have any adverse side effects. The cost of Psorinum Therapy is significantly less than the chemotherapies which should be a great relief to the patients coming from the lower economic strata.”
   
The primary outcome measures of the study were to assess the radiological tumor response rates  and to assess how many participants survived at least 1 yr, 2 yrs, 3 yrs, 4 yrs, and finally, after 5 yrs of the study. The drug Psorinum (an alcoholic extract of scabies, slough and pus cells) was administered orally at 0.02ml/Kg body weight/day as a single dose in empty stomach and ongoing for complete course duration of 2 years to all the participants along with allopathic and homeopathic supportive cares. Among the 95 participants who were included in the final analysis at the end of the study, 58 (61.05%) diagnosed at stage IV. Complete tumor response occurred in 19 (20%) cases and partial tumor response occurred in 28 (29.47%) cases. 82 (86.32%) of them survived at least 1 yr, 70 (73.68%) survived at least 2 yrs, 58 (61.05%) survived at least 3 yrs, 49 (51.58%) survived at least 4 yrs, and 42 (44.21%) of them survived at least 5 yrs. These participants did not receive chemotherapy, radiation therapy, or any other investigational cancer treatments.   

The study mentor and ASCO member, Jaydip Biswas who is the director of the Chittaranjan National Cancer Institute (CNCI), Kolkata, India says, “the investigational drug ‘Psorinum’ works as an immunomodulator by stimulating the tumoricidal activities of the NK and NK T cells. I believe the study led by Aradeep Chatterjee provides new insights in improving the conventional cancer cares to treat lung cancer. We are now planning for a phase- III clinical trial on Psorinum Therapy as a final follow up of the study. ”
   
The research-abstract is published in the print and online version of the world’s top-ranked cancer journal ‘Journal of Clinical Oncology’ in the May 20, 2010 supplement.

CONTACT

Mobile: 91- 9903890351
Phone: 91-33-25342012
Fax: 91-33-30121073
Email: arodeep@gmail.com
Address: Critical Cancer Management Research Centre & Clinic (CCMRCC)
              381 S K Deb Road, Kolkata 700048, West Bengal, India

# # #

Critical Cancer Management Research Centre & Clinic (CCMRCC) is a non- profit privately organized institute to integrate evidence based complementary & alternative cancer therapies with conventional cancer cares. It is a unit under the Dr. Rabindranath Chatterjee Memorial Cancer Trust (RCMCT) and licensed under the clinical establishment act of Department of Health & Family Welfare, West Bengal India. CCMRCC is one of the world leading cancer treatment facilities. An outpatient clinic specializing in the treatment of the entire range of cancers, this institute is dedicated to providing a caring environment that emphasizes the unique biological, physical and psychological qualities of each person we treat.